Figure 3. Tumor-infiltrating lymphocytes, molecular features, and PD-L1 expression of CRPC samples from RMH cohort.

(A) Tumor-infiltrating T lymphocyte quantitation in 50 mCRPC biopsies, with MMR status according to the different orthogonal assays (MSI_MUT; MSI_IHC; MSI_MSINGS; mutation load), ordered from left to right by T cell infiltration score. A sample from 1 dMMR patient was not used for this analysis since it was a TURP sample taken at time of CRPC. Blue squares mark altered biomarker. (B) Stacked bar chart depicts proportion of PD-L1 immunohistochemical positivity (e.g., Supplemental Figure 3A) in samples reviewed by pathologists blinded to dMMR results in 51 mCRPC samples (n = 10 dMMR, n = 41 pMMR). (C) Dot plot showing the correlation between PD-L1 expression and T cell infiltration in mCRPC biopsies (n = 29). The y axis depicts total T cell infiltration defined as n of T cells/mm² using a negative binomial regression model; there was an IRR of 3.91 (95% CI, 1.45–10.53; P = 0.007) for patients with PD-L1 > 0. Filled circles represent pMMR; open circles represent dMMR.